← All trials
NCT05392634
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 2, 2022
- Primary completion
- Feb 2, 2023
- Completion date
- Nov 1, 2023
- First posted
- May 26, 2022
- Last posted
- May 31, 2022
- Enrollment
- 98
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of RussiaLead sponsor
- Government of RussiaOverall official - principal investigator
- Government of RussiaReponsible party - principal investigator
- The Foundation for Cancer Research Support (RakFond)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.